4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Atea Pharmaceuticals, Inc. (AVIR) operates in the Biotechnology industry and is headquartered in Boston, United States with about 55 employees. Its market capitalization is roughly $376 million. In the fiscal year ended 2025-12-31, AVIR reported $0M in revenue and ($158M) in net income.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($181M) | ($193M) | ($164M) | ($131M) |
| Net Income | ($158M) | ($168M) | ($136M) | ($116M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($48M) | ($55M) | ($46M) | ($41M) | ($39M) |
| Net Income | ($45M) | ($45M) | ($42M) | ($37M) | ($34M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $315M | $465M | $595M | $667M | — |
| Total Liabilities | $40M | $26M | $40M | $26M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AVIR viewer.
About TickerBase · Data methodology & sources